摘要
目的评价唑来磷酸联合89Sr治疗前列腺癌骨转移的临床疗效及不良反应。方法将去势治疗后的前列腺癌骨转移伴不同程度骨痛的39例患者随机分为两组,唑来磷酸组(A组,n=18):唑来磷酸4mg加生理盐水100ml,静脉滴注30min以上,每28d1次,2～3次;唑来磷酸联合89Sr组(B组,n=21):唑来磷酸4mg(方法同上),89Sr148～222MBq/kg体重。分别观察镇痛效果、骨转移灶的变化、前列腺特异性抗原(PSA)及不良反应等。结果治疗前后A组疼痛评分分别为6.05±3.55和3.61±1.97,tPSA分别为(66.32±24.21)和(24.53±9.94)μg/L(P<0.001);B组疼痛评分分别为5.93±3.71和1.66±0.91,tPSA分别为(67.41±23.85)和(20.56±8.64)μg/L(P<0.001)。两组骨转移灶消失或减少率分别为55.56%和71.43%。均未出现严重的不良反应。B组止痛和减少骨转移灶效果优于A组(P<0.05)。结论唑来磷酸联合89Sr对去势治疗后的前列腺癌骨转移骨痛的止痛效果明显,可显著减少骨转移灶,较单独应用唑来磷酸效果好,是一种治疗晚期前列腺癌的有效方法。
Objective To estimate clinical curative efficacy and adverse reaction of combining therapy of 89Sr chloride and zoledronic for bone metastases in the patients with prostate cancer.Methods 39 cases of metastatic prostate cancer with bone pain after androgen deprivation therapy were divided into two groups randomizationly：zoledronic acid group（A group,n=18） and combine 89SrCl2 and zoledronic acid group（B group,n=21）.89SrCl2 and zoledronic were administrated iv respectively for the palliative treatment of metastatic bone pain.The curative effects in patients were investigated,including palliation of pain,change of metastatic focus,the tumor sign of PSA,and the adverse reaction.Results Before and after therapy in group A,the pain grades was 6.05±3.55 and 3.61±1.97,tPSA was （66.32±24.21） and （24.53±9.94）μg/L（P0.001）,respectively; in group B,the pain grades was 5.93±3.71 and 1.66±0.91、tPSA was （67.41±23.85） and （20.56±8.64）μg/L（P0.001）.In two groups,the rate of disappear or reduce for metastatic focus were 55.56% and 71.43%.The palliation of pain and change of metastatic focus were better in group B than in group A （P0.05）.Without detecting the serious adverse reaction in all treatment patients.Conclusion s It is shown that the curative efficacy of acesodyne is evident after 89SrCl2 combine zoledronic therapy in patients suffering from bone metastase with prostate cancer.It is an effective therapeutic method for the palliation of pain from bone metastases especially to the patients with multiple metastases.
出处
《现代泌尿生殖肿瘤杂志》
2010年第5期213-215,共3页
Journal of Contemporary Urologic and Reproductive Oncology
关键词
锶放射性同位素
前列腺肿瘤
治疗
Strontium radioisotopes
Prostatic neoplasms
Therapy
